Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.
3.

Long-acting injectable naltrexone for the treatment of alcohol dependence.

Mannelli P, Peindl K, Masand PS, Patkar AA.

Expert Rev Neurother. 2007 Oct;7(10):1265-77. Review.

PMID:
17939765
4.

A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence.

Johnson BA, Ait-Daoud N, Aubin HJ, Van Den Brink W, Guzzetta R, Loewy J, Silverman B, Ehrich E.

Alcohol Clin Exp Res. 2004 Sep;28(9):1356-61.

PMID:
15365306
5.

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.

Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW; Vivitrex Study Group.

JAMA. 2005 Apr 6;293(13):1617-25. Erratum in: JAMA. 2005 Apr 27;293(16):1978. JAMA. 2005 Jun 15:293(23):2864.

PMID:
15811981
6.

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial.

Kranzler HR, Wesson DR, Billot L; DrugAbuse Sciences Naltrexone Depot Study Group.

Alcohol Clin Exp Res. 2004 Jul;28(7):1051-9.

PMID:
15252291
8.

Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery.

Roozen HG, de Waart R, van den Brink W.

Eur Addict Res. 2007;13(4):201-6.

PMID:
17851241
9.

Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats.

Bartus RT, Emerich DF, Hotz J, Blaustein M, Dean RL, Perdomo B, Basile AS.

Neuropsychopharmacology. 2003 Nov;28(11):1973-82.

10.

Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.

Lobmaier PP, Kunøe N, Gossop M, Waal H.

CNS Neurosci Ther. 2011 Dec;17(6):629-36. doi: 10.1111/j.1755-5949.2010.00194.x. Review.

PMID:
21554565
11.

Long-acting injectable naltrexone for the management of patients with opioid dependence.

Kjome KL, Moeller FG.

Subst Abuse. 2011;5:1-9. doi: 10.4137/SART.S5452. Epub 2011 Feb 6.

12.
13.

Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.

Syed YY, Keating GM.

CNS Drugs. 2013 Oct;27(10):851-61. doi: 10.1007/s40263-013-0110-x. Review.

PMID:
24018540
14.

Long-acting depot formulations of naltrexone for heroin dependence: a review.

Krupitsky EM, Blokhina EA.

Curr Opin Psychiatry. 2010 May;23(3):210-4. doi: 10.1097/YCO.0b013e3283386578. Review.

PMID:
20224403
15.

Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.

Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR.

Alcohol Clin Exp Res. 2011 Oct;35(10):1804-11. doi: 10.1111/j.1530-0277.2011.01524.x. Epub 2011 May 16.

PMID:
21575016
16.

A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.

Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O'Brien CP.

Am J Psychiatry. 2010 Jun;167(6):668-75. doi: 10.1176/appi.ajp.2009.08060852. Epub 2010 Mar 15.

17.

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.

Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC.

Alcohol Clin Exp Res. 2006 Mar;30(3):480-90.

PMID:
16499489
18.

Pharmacological treatment of alcohol dependence: a review of the evidence.

Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT.

JAMA. 1999 Apr 14;281(14):1318-25.

PMID:
10208148
19.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
20.

Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.

Brooks AC, Comer SD, Sullivan MA, Bisaga A, Carpenter KM, Raby WM, Yu E, O'Brien CP, Nunes EV.

J Clin Psychiatry. 2010 Oct;71(10):1371-8. doi: 10.4088/JCP.09m05080ecr. Epub 2010 Jul 13.

Supplemental Content

Support Center